Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer
Completed
Conditions studied: Breast Cancer
In brief
RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving anastrozole may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about how anastrozole works in the body. PURPOSE: This research study is looking at the pharmacogenetics of anastrozole in postmenopausal women with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) stage I, stage II, or stage III breast cancer.
Key facts
- Study ID
- NCT00283608
- Run by
- Mayo Clinic
- People needed
- 1000
- Starts
- 2005-07-01
- Expected to finish
- 2010-03-01
- Last updated by the study team
- 2011-05-16
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States
- Mayo Clinic in Florida — Jacksonville, Florida, United States
- Mayo Clinic — Rochester, Minnesota, United States
- M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.